As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > REGULATORY
REGULATORY
- Senior Bureaucrat Chided for Leaking Draft Clinical Research Bill
September 4, 2019
- Japan, Vietnam Regulators to Hold 1st Joint Symposium Next Month
September 4, 2019
- Japan Drug Production Up 2.8% to 6.9 Trillion Yen in 2018: MHLW
September 2, 2019
- MHLW’s Health Policy Bureau Requests Increased Budget for Core Hospitals, Centers for Pediatric and Rare Diseases
September 2, 2019
- MEXT Requests 103.4 Billion Yen to Fuel Healthcare R&D in FY2020
September 2, 2019
- METI Seeks 5.1 Billion Yen in FY2020 to Develop Technology Platforms for Cell and Gene Therapies
September 2, 2019
- Astellas’ “Post-Nesp” Renal Anemia Drug Now in Line for September Approval, 1st Forteo Biosimilar Too
August 30, 2019
- MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug
August 30, 2019
- Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
August 29, 2019
- Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
- MHLW Seeks Record 32.6 Trillion Yen Budget for FY2020
August 28, 2019
- Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
- Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
- Public Knowledge-Based Filing OK’ed for Busulfex Use in Lymphoma HSCT
August 27, 2019
- Evenity under PMDA Risk Review
August 27, 2019
- Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
- Japan Eyes 1st Revision in 15 Years for Cancer Drug Development Guidelines to Deal with Rare Subtypes, Tumor-Agnostic Indications
August 27, 2019
- AbbVie’s Venetoclax Now in Line for September OK; Tecentriq’s Breast Cancer Use, 2nd Biosimilars and More
August 26, 2019
- MHLW to Seek Budgets to Forge “Drugs for Specific Use” System for FY2020
August 23, 2019
- Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies
August 23, 2019
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…